Amgen Presents Preclinical And Clinical Data From Oncology Programs

Amgen (NASDAQ:AMGN) announced data generated by the company’s robust oncology research and development programs in the areas of apoptosis (programmed cell death) and cell growth regulation. The data, presented at the American Association for Cancer Research (AACR) Annual Meeting in San Diego were from five preclinical studies evaluating anti-tumor activity, pharmacodynamics, and potential pre-clinical and clinical biomarkers for investigational molecules AMG 655, AMG 479 and AMG 102.

More: continued here

Filed under: Cancer on April 18th, 2008